# A novel typing method for Clostridium perfringens using multiplex recombinase polymerase amplification and CRISPR/Cas12a

## TL;DR

This paper introduces a fast and accurate method to identify different types of Clostridium perfringens using a CRISPR-based system, aiding in early disease diagnosis.

## Contribution

A new, rapid, and instrument-free typing method for C. perfringens using RPA and CRISPR/Cas12a is developed.

## Key findings

- The Cp-MRC12a method can complete typing in 1 hour with high sensitivity and specificity.
- It detects as few as 10 copies/μL for type A and 100 copies/μL for types B-E with no cross-reactivity.
- The method reliably identifies C. perfringens in clinical and spiked samples.

## Abstract

Distinct toxinotypes of Clostridium perfringens cause different diseases in animals and humans. Rapid and accurate typing methods remain essential for early diagnosis, effective intervention, and reduced mortality. In this study, we designed specific primer pairs and crRNA sequences targeting the α, β, ε, and ι toxin genes of C. perfringens and constructed a rapid, sensitive, accurate and instrument-free method for typing of C. perfringens. This typing method of C. perfringens based on the multiplex recombinase polymerase amplification (RPA)-assisted CRISPR/Cas12a system, termed Cp-MRC12a, can be completed in 1 h. The Cp-MRC12a assay shows high sensitivity with a detection limit of 10 copies/μL for the type A strain and 100 copies/μL for the type B-E strains and high specificity without cross-reactivity to non-target bacteria, and demonstrates a reliable performance in detecting clinical and spiked samples. Collectively, Cp-MRC12a provides a robust and practical approach for the typing of C. perfringens strains, offering substantial advances for early disease diagnosis and pathogen identification.